>> Eva: DR. JEN IS BACK WITH US, TALKING ABOUT PROMISING NEWS TALKING ABOUT PROMISING NEWS WITH BREAST CANCER. WITH BREAST CANCER. >> Dr. Ashton: THIS JUST CAME >> Dr. Ashton: THIS JUST CAME OFF EMBARGO THIS MORNING FROM OFF EMBARGO THIS MORNING FROM NOVA RTIS, PRESENTED AT THE NOVA RTIS, PRESENTED AT THE LARGEST CANCER CONFERENCE ABOUT LARGEST CANCER CONFERENCE ABOUT A DRUG FDA APPROVED. A DRUG FDA APPROVED. THIS IS FDA APPROVED FOR LATER THIS IS FDA APPROVED FOR LATER STAGE BREAST CANCER, CERTAIN STAGE BREAST CANCER, CERTAIN TYPE AND PRESENTING ENCOURAGING TYPE AND PRESENTING ENCOURAGING DATA ABOUT USE IN EARLIER-STAGE DATA ABOUT USE IN EARLIER-STAGE ESTROGEN RECEPTOR POSITIVE, ESTROGEN RECEPTOR POSITIVE, PROGESTERONE POSITIVE HR-2 PROGESTERONE POSITIVE HR-2 NEGATIVE EARLY STAGE BREAST NEGATIVE EARLY STAGE BREAST CANCER REDUCING RECURRENCE. CANCER REDUCING RECURRENCE. THIS IS IMPORTANT, THIS IS ABOUT THIS IS IMPORTANT, THIS IS ABOUT 100,000 OR MORE WOMEN WHO HAVE 100,000 OR MORE WOMEN WHO HAVE THIS TYPE OF BREAST CANCER AND A THIS TYPE OF BREAST CANCER AND A LOT OF TIMES WE HEAR MEDICAL LOT OF TIMES WE HEAR MEDICAL HEADLINES AND DEVELOPMENT FOR HEADLINES AND DEVELOPMENT FOR METROPOLISA STATIC BREAST CANCER METROPOLISA STATIC BREAST CANCER AND THERE ARE A LOT OF WOMEN AND THERE ARE A LOT OF WOMEN DIAGNOSED WITH EARLIER STAGE DIAGNOSED WITH EARLIER STAGE FORM OF THE DISEASE FOR WHOM FORM OF THE DISEASE FOR WHOM ADVANCES AND DEVELOPMENT IS A ADVANCES AND DEVELOPMENT IS A MAJOR THING. MAJOR THING. THIS IS ENCOURAGING NEWS AND THIS IS ENCOURAGING NEWS AND SPEAKS TO INCREDIBLE PROGRESS SPEAKS TO INCREDIBLE PROGRESS WE'RE MAKING IN BREAST CANCER. WE'RE MAKING IN BREAST CANCER. >> Demarco: IT IS CONSIDERED A >> Demarco: IT IS CONSIDERED A GAME-CHANGER? GAME-CHANGER? >> Dr. Ashton: YOU KNOW ME, I >> Dr. Ashton: YOU KNOW ME, I TEND TO SHY AWAY FROM HYPERBOLE, TEND TO SHY AWAY FROM HYPERBOLE, IF YOU ARE TALKING ABOUT THOSE IF YOU ARE TALKING ABOUT THOSE WOMEN WHO ARE POTENTIALLY A WOMEN WHO ARE POTENTIALLY A CANDIDATE FOR THIS DRUG, OF CANDIDATE FOR THIS DRUG, OF COURSE. COURSE. THEY MIGHT CONSIDER IT THAT WAY. THEY MIGHT CONSIDER IT THAT WAY. THE MORE OPTIONS WE HAVE IN OUR THE MORE OPTIONS WE HAVE IN OUR TOOL BOX FOR THIS TYPE OF BREAST TOOL BOX FOR THIS TYPE OF BREAST CANCER, THE BETTER. CANCER, THE BETTER. THIS IS JUST AN EXAMPLE, THIS IS JUST AN EXAMPLE, IMPORTANT DATA AND COULD BE IMPORTANT DATA AND COULD BE AVAILABLE FOR THOSE WOMEN SOON. AVAILABLE FOR THOSE WOMEN SOON. >> ESPECIALL